Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Google Inc (GOOG) vs 10X Genomics Inc (TXG) Price & Performance

Google IncTrade
10X Genomics IncTrade

Price performance (Past 24H)

Key statistics

Google Inc vs 10X Genomics Inc — how do they compare? Google Inc trades at $371.28 (market cap $4.52T), while 10X Genomics Inc trades at $42.57 (market cap $5.81B). The key difference: Google Inc is far larger — about 778× 10X Genomics Inc's market cap, and Google Inc pays a 0.24% dividend while 10X Genomics Inc pays none. Which is the better fit depends on your goals.

GOOGTXG
Market Cap
$4.52T$5.81B
Volume
1,511,127
Sector
TechnologyHealth
52-Week High
$399.06$45.80
52-Week Low
$183.77$11.34
Enterprise Value
$4.49T$5.35B
Dividend Yield
0.24%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Google Inc

Alphabet (GOOG) trades at $370.43, up 3.67% on the day, with strong bullish momentum from recent earnings beats and a consensus analyst price target of $457.50. The stock shows robust fundamentals with 2025 revenue of $402.84B, net income margin of 37.92%, and consistent cash flow growth. Technical indicators are bullish, with the current price near resistance at $374, while sentiment is positive due to Warren Buffett's recent endorsement and AI-driven growth prospects.

Outlook remains favorable with earnings growth and AI expansion as key catalysts, though regulatory risks and market volatility pose challenges. The stock offers upside potential aligned with analyst targets, supported by high institutional ownership and strong profitability metrics.

10X Genomics Inc

10x Genomics (TXG) trades at $42.56, down 7.07% today, with mixed technical signals showing bullish moving averages but overbought RSI levels. The company demonstrates strong revenue stability around $640M annually and improving profitability trends, with net losses narrowing significantly from -$255M in 2023 to -$44M in 2025. Recent strategic moves include the Proteintech Genomics acquisition and Cleveland Clinic collaboration to expand multiomics capabilities.

While the company shows promising margin improvement and strategic growth initiatives, investors face valuation concerns with elevated P/S and EV/EBITDA ratios. The mixed analyst sentiment (45% buy, 50% hold) and consensus price target below current levels suggest cautious optimism. Key risks include ongoing profitability challenges and competitive pressures in the life sciences tools market.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Google Inc

Alphabet Inc. operates as a holding company. The Company, through its subsidiaries, provides web-based search, advertisements, maps, software applications, mobile operating systems, consumer content, enterprise solutions, commerce, and hardware products.

Read more on GOOG

About 10X Genomics Inc

10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.

Read more on TXG